EP0542372A1 — 2-Substituted saccharin derivative proteolytic enzyme inhibitors
Assigned to Sanofi SA · Expires 1993-05-19 · 33y expired
What this patent protects
Novel 2-substituted saccharins which inhibit the enzymatic activity of proteolytic enzymes are useful in the treatment of degenerative diseases and have the formula wherein: L is -O-, -S-, -SO- or -SO₂-; m and n are each independently 0 or 1; R₁ is substit…
USPTO Abstract
Novel 2-substituted saccharins which inhibit the enzymatic activity of proteolytic enzymes are useful in the treatment of degenerative diseases and have the formula wherein: L is -O-, -S-, -SO- or -SO₂-; m and n are each independently 0 or 1; R₁ is substituted phenyl, heterocyclyl or substitued heterocyclyl or, when L is -O- and n is 1, R₁ is cycloheptatrienon-2-yl or, when L is -S- and n is 1, R₁ is cyano or lower-alkoxythiocarbonyl or, when L is -SO₂- and n is 1, R₁ is lower-alkyl or trifluoromethyl; R₂ is hydrogen, lower-alkoxycarbonyl, phenyl or phenylthio; and R₃ and R₄ are each hydrogen or various substituents, and processes for preparation and pharmaceutical compositions and method of use thereof are disclosed.
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.